CI
NYSE · Health Care
The Cigna Group
$279.46
-3.62 (-1.28%)
CI News30 articles
AI-Driven Healthcare Fraud Surge Strains Insurers, Coverage Gaps Widen
AI is fueling healthcare fraud with fake medical records and bot calls, driving up costs and exposing coverage gaps as insurers scramble to adapt.
UnitedHealth Rises as Analysts See Easing Medical Costs
UnitedHealth shares climbed 5.7% after Bank of America upgraded the stock to Buy and Morgan Stanley raised its price target, citing easing medical costs and a favorable Q2 setup.
UnitedHealth Drops Premarket After Berkshire Exits Stake
UnitedHealth shares dropped 4.8% in premarket trading after Berkshire Hathaway disclosed it sold its stake in the insurer, dampening sentiment despite strong Q1 results.
UnitedHealth Shares Surge as Investors Bet on Recovery, PBM Reform
UnitedHealth shares climbed 3.1% as the company unveiled a new Optum Rx fee-based pricing model and raised 2026 profit guidance, signaling a potential turnaround.
Blue Cross Blue Shield $2.67B Settlement Payouts Begin in May 2026
Blue Cross Blue Shield settlement payments start in May 2026 for eligible claimants in a $2.67 billion antitrust case. Payouts vary based on claims and premiums, with an estimated average of $333.
Cigna Exits ACA Market, 369,000 Members Need New Plans for 2027
Cigna Group will exit the ACA individual insurance market after 2026, affecting 369,000 members in 11 states who must find new coverage for 2027.
Blue Cross Blue Shield Settlement Payouts to Begin in May
Payments from the $2.67 billion Blue Cross Blue Shield antitrust settlement begin in May 2026 for eligible claimants who filed by November 2021.
UnitedHealth Shares Drop Ahead of Q1 Report, Sector Under Pressure
UnitedHealth Group shares declined sharply Friday, extending weekly losses as the market anticipates first-quarter results. The health insurance sector broadly retreated.
UnitedHealth Gains Amid Medicare Rate Uncertainty and ACA Investigations
UnitedHealth shares edged higher as investors monitored upcoming Medicare Advantage payment decisions and a House Republican probe into ACA insurers. The sector traded mixed.
UnitedHealth Dips After Hours as Medicare Rate Decision Looms
UnitedHealth shares edged lower in extended trading Monday as healthcare stocks underperformed the broader market. Investors are focused on upcoming Medicare Advantage reimbursement updates, with the final rates expected in early April.
Bitmine Stock Slides 7% as Ether Decline Pressures $10.7B Crypto Holdings
Bitmine stock dropped 7.3% as ether slid 5.1%, threatening the value of its massive $10.7B crypto treasury. The company warned of risks to asset values and capital-raising ability.
Gold Dips Below $4,000 as Dollar Strengthens and Fed Hawkishness Weighs
Gold slipped under $4,000 an ounce for the first time in seven months as the dollar strengthened and traders increased bets on further Fed rate hikes, sparking a broad precious metals selloff.
Hershey's $1.7B Rally on Cocoa Margin Hopes Faces Weather Risk
Hershey shares surged 4.9% to $179.27, adding $1.7 billion in value, as investors bet on margin recovery from lower cocoa costs. However, rising cocoa prices due to Ivory Coast weather risks threaten the rebound.
Iovance Biotherapeutics Stock Surges on $89.7 Million ATM Offering
Iovance shares rose 9.4% after launching an $89.65 million ATM stock sale, as investors balance dilution risks against the potential for accelerated Amtagvi revenue growth.
Viking Therapeutics Surges on Obesity Drug Hopes
Viking Therapeutics shares climbed 6% to $34.30 as investors bet on upcoming Phase 3 data for its obesity drug VK2735, expected in Q3 2026.
Catheter Precision Surges 34.5% Premarket on Patent News and Resale Filing
Catheter Precision (VTAK) surged 34.5% premarket following a flurry of announcements including new patents, a sports partnership, and a resale share filing for 68.1 million shares.
Nexentis Shares Surge 156% on AI Drug Discovery Pact, Then Retreat
Nexentis shares skyrocketed 156% after announcing an AI drug discovery deal and a $2.9 million stock-and-warrant offering, but declined 26% in after-hours trading amid dilution concerns.
AbbVie Acquires Apogee Therapeutics for $10.9B in Cash, Bolstering Pipeline
AbbVie announced a $10.9 billion cash acquisition of Apogee Therapeutics, adding a promising eczema treatment to its pipeline as it seeks to offset declining Humira sales.
AbbVie to Acquire Apogee Therapeutics for $10.9 Billion in Cash
Apogee Therapeutics stock jumped 47% after AbbVie agreed to buy the company for $135.11 per share in cash, adding late-stage eczema drug zumilokibart.
PG&E Outages Hit 9,000 Across Three Counties Amid Fire Weather
PG&E outages affected over 9,000 customers in Monterey, Clovis, and Shasta County amid storms and fire weather, underscoring utility challenges in maintaining reliability during peak summer demand.
Wolfspeed Surges 18% Then Files Share Resale, Testing AI Chip Rally
Wolfspeed shares surged 18% before filing to register 24 million shares for resale, raising dilution concerns. The silicon carbide chipmaker's AI-driven rally faces a test when markets reopen.
CervoMed Shares Surge on Patent News, Then Retreat After $10M Stock Offering
CervoMed shares surged to $7.75 after a U.S. patent allowance for neflamapimod in pure DLB, but gave back most gains after announcing a $10 million stock offering at $4 per share. The stock last traded at $4.14, up 8.7%.
UniQure Holds Gains as FDA Signals Path for Huntington's Gene Therapy Filing
UniQure shares jumped 78.4% after the FDA said Phase I/II data could support an accelerated-approval filing for its Huntington's disease gene therapy AMT-130. A BLA is planned for Q3 2026.
The Agency Expands in Central America with New Belize Office in Placencia
The Agency has opened its first Belize office in Placencia, expanding its Central America network. The move aims to capture rising foreign buyer interest, though past fraud cases remain a warning for investors.
FDA Greenlights uniQure's Accelerated Approval Path for Huntington's Gene Therapy
uniQure shares surged 78% premarket after the FDA agreed to accept three-year Phase I/II data as the basis for an accelerated approval filing for AMT-130 in Huntington's disease, reviving the near-term U.S. path for the potential first disease-modifying treatment.
Outlook Therapeutics Surges on FDA Review of Wet AMD Treatment
Outlook Therapeutics shares jumped 30% after the FDA accepted its resubmitted BLA for ONS-5010/LYTENAVA, setting a PDUFA target date of July 29, 2026.
Bitmine Stock Rises as Ethereum Holdings Hit 5.62 Million ETH
Bitmine Immersion Technologies (BMNR) jumped 6.21% to $17.11 after revealing its Ethereum treasury reached 5,620,754 ETH, representing 4.66% of total supply.
Intellia Therapeutics Surges 23% on Promising Phase 3 Data for CRISPR Therapy
Intellia Therapeutics shares surged 23% to $14.92 after Phase 3 data showed lonvo-z reduced hereditary angioedema attacks by up to 91% versus placebo, with FDA filing as the next catalyst.
AmEx to Acquire TheFork from TripAdvisor for $700M, Expanding Dining Network
American Express will acquire TheFork from TripAdvisor for $700 million in cash, expanding its dining network to 75,000 bookable venues and allowing TripAdvisor to focus on its Experiences segment.
BitMine's Ethereum Holdings Surge to 5.62M ETH, Stock Climbs Ahead of Preferred Debut
BitMine Immersion Technologies shares jumped 6.7% to $17.19 after revealing a massive Ethereum treasury of 5.62 million ETH, ahead of its Series A preferred stock listing on the NYSE.